Navigation Links
Targeted investigational therapy potential to overcome crizotinib resistance in lung cancers
Date:10/20/2013

BOSTON PF-06463922, an investigational drug being developed by Pfizer Inc., has the potential to become a new treatment option for patients who have lung cancer harboring abnormalities in the ALK gene, according to preclinical results presented here at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held Oct. 19-23.

About 3 to 5 percent of lung cancers harbor ALK gene abnormalities. The drug crizotinib (Xalkori), which blocks ALK protein kinase activity, was approved in August 2011 by the U.S. Food and Drug Administration for the treatment of patients who have these lung cancers. Although robust responses to crizotinib are observed for lung cancers harboring ALK gene abnormalities, the majority eventually become resistant to the effects of the drug. In many cases, resistance arises because of genetic mutations in ALK.

"Resistance to targeted therapies such as crizotinib is a major challenge when treating patients with cancer," said Tod Smeal, Ph.D., associate research fellow in the Oncology Research Unit at Pfizer Inc. in San Diego, Calif. "Our goal is to take advantage of everything we have learned about designing drugs that target kinases like ALK and the ways in which lung cancers become resistant to crizotinib to develop the best next-generation ALK inhibitor we can.

"Our preclinical studies suggest that we are making progress toward achieving our goal: PF-06463922 has potent ALK-inhibiting activity, it is capable of inhibiting all the crizotinib-resistant ALK mutants so far detected in patients, and it can efficiently access the brain. We are excited about these preclinical results and very hopeful that they will translate into meaningful responses in the clinic."

After carefully designing PF-06463922, Smeal and colleagues first showed in cell assays that it potently inhibited the activity of ALK and all eight of the mutant forms of ALK known to cause resistance to crizotinib
'/>"/>

Contact: Lauren Riley
lauren.riley@aacr.org
215-446-7155
American Association for Cancer Research
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Targeted therapeutics for colon cancer to be presented at AACR meeting
2. First targeted nanomedicine to enter human clinical studies
3. Highly targeted irradiation as good as whole breast radiotherapy in early stage cancer
4. Dana-Farber: Study reports first success of targeted therapy in type of non-small cell lung cancer
5. Inflammatory pathway spurs cancer stem cells to resist HER2-targeted breast cancer treatment
6. Killer infections targeted by hospital study
7. Lower risk of serious side-effects in trials of new targeted drugs
8. Treating drug resistant cancer through targeted inhibition of sphingosine kinase
9. Pitt: Targeted oxidation-blocker prevents secondary damage after traumatic brain injury
10. Deadly witch hunts targeted by grassroots womens groups
11. Large lung cancer study shows potential for more targeted therapies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... January 23, 2015 VogueQueen is a seasoned ... prices and many designers are thrilled to have it lead ... announces its new collection of prom dresses for the global ... drive the strategic vision and he focuses on continuing the ...
(Date:1/22/2015)... the premier women’s dress supplier, has recently released its ... of AngelWeddingDress.com to find more details. , Many ... a bridal party. AngelWeddingDress offers a variety of gorgeous ... wedding dresses are specially designed for 2015. , AngelWeddingDress ...
(Date:1/22/2015)... New York, New York (PRWEB) January 22, 2015 ... filed after Fresenius Medical Care recalled its GranuFlo ... the federal multidistrict litigation underway in U.S. District Court, ... an Order dated January 20th, the Court has remanded ...
(Date:1/22/2015)... January 22, 2015 Joan Lunden, award-winning ... speaker at the upcoming 32nd Annual Miami Breast ... Physicians’ Education Resource®, LLC (PER®) , shares that “a ... gone undetected if she had not followed up her ...
(Date:1/22/2015)... January 22, 2015 IsoComforter, Inc. has introduced ... with patented IsoTube design to treat specific body parts and ... most progressive and easy to use patented cold therapy machine ... sports related orthopedic and muscle injuries. IsoComforter has become ...
Breaking Medicine News(10 mins):Health News:VogueQueen Unveils New Designs of Prom Dresses for 2015 2Health News:AngelWeddingDress Has Recently Released Its Collection Of 2015 Maternity Wedding Dresses 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 5Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 6Health News:IsoComforter Introduces Best of Class Cold Therapy Product to the Worldwide Market 2
... TUESDAY, Feb. 15 (HealthDay News) -- Some adults may want to ... the early age of 3, children have a sense of what,s ... with each other after working together to earn a reward, even ... to keep all of the prize without sharing. In the ...
... HealthDay Reporter , TUESDAY, Feb. 15 (HealthDay News) ... common than thought among high school athletes, especially among ... finds. "The risk is that we,re often dealing ... perfect their performance, and sometimes they overdo it," said ...
... Feb. 15 (HealthDay News) -- In women with bipolar ... episodes and more severe symptoms, researchers have found. ... offer evidence that premenstrual flare-ups of mood symptoms may ... disorder in reproductive-age women, said Dr. Rodrigo Dias and ...
... Feb. 15, 2011 Researchers from Korea ... sedation (BPS) using propofol in combination with midazolam ... better patient cooperation, and similar adverse event profiles ... the first prospective study of BPS in direct ...
... , CHG cloths more effective in reducing risk for ... from MRSA or VRE, May be beneficial for both ICU and ... new study from Rhode Island Hospital has found a reduced risk ... cloths for daily bathing instead of soap and water. The study ...
... of the population, suffers from daily heartburn or other ... and dental erosions. Until recently, many of these patients ... or worsening of their symptoms while treatment options were ... Round Rock is offering a new procedure to patients ...
Cached Medicine News:Health News:Stress Fractures Hitting High School Athletes 2Health News:Stress Fractures Hitting High School Athletes 3Health News:Fluctuating Hormones Linked to More Severe Bipolar Symptoms 2Health News:Study compares balanced propofol sedation with conventional sedation for therapeutic GI endoscopic procedures 2Health News:Study compares balanced propofol sedation with conventional sedation for therapeutic GI endoscopic procedures 3Health News:Study compares balanced propofol sedation with conventional sedation for therapeutic GI endoscopic procedures 4Health News:Using chlorhexidine gluconate baths to reduce hospital-acquired infections 2Health News:Scott & White Healthcare -- Round Rock performing surgery without incisions for heartburn 2
(Date:1/23/2015)... Jan. 23, 2015  Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT), announced ... trial of Lixte,s lead compound, LB‑100, is being conducted, has ... John S. Kovach , M.D., the founder and President of ... completed at a single site. Accrual of patients, however, was ...
(Date:1/23/2015)... , Jan. 23, 2015  CytoSorbents Corporation (NASDAQ CM: ... CytoSorb® extracorporeal cytokine adsorber to reduce deadly inflammation ... receipt of $385,642, net of transaction costs, in ... Technology Business Tax Certificate Transfer Program sponsored by ...
(Date:1/23/2015)... BOSTON , January 23, 2015 Heptares ... is delighted to announce that the Malcolm Campbell ... Congreve (Vice President of Chemistry), Fiona Marshall ... (Chief Executive Officer and co-founder) for the seminal contributions to ...
Breaking Medicine Technology:Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 2CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 3Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 2Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 3Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 4
... Oct. 13, 2011 The American Association for Homecare ... to include any additional budgetary spending cuts that will ... in its recommendations to Congress. Over the years, ... Americans, while also producing cost-savings in the health care ...
... NEW YORK, Oct. 13, 2011 Techstreet, ... providing corporate subscriptions to the International Society for Pharmaceutical ... publications it currently offers. The online subscription service is ... it provides unlimited access to the latest ISPE Documents ...
Cached Medicine Technology:American Association for Homecare Calls on Joint Deficit Committee in Congress to Preserve Homecare Access for Millions of Americans 2Techstreet and the ISPE Extend Partnership to Expedite Drug Research with Subscription Offering for Life Science Engineers 2
PacePath is a comprehensive anatomic pathology software system that is the culmination of more than five years of development and testing by leading industry experts....
... optimal speed, efficiency and results, without the ... Most importantly, EZLink meets strategic laboratory network ... in the same facility - without sacrificing ... paperless laboratory, the network can be linked ...
Velocity works cooperatively with LabSofts LabNet LIS, allowing the convenience of 24-hour access to information from satellite lab locations, hospitals, physician offices and even homes....
A comprehensive and cost effective LIS solution for the Physicians Office Laboratory....
Medicine Products: